Skip to main content
. 2016 Jun 3;95(22):e3780. doi: 10.1097/MD.0000000000003780

TABLE 3.

Proportions of Patients Treated With Tenofovir Plus Emtricitabine or Lamivudine and Either Atazanavir/Ritonavir or Darunavir/Ritonavir or Lopinavir/Ritonavir or a Non-Nucleoside Reverse Transcriptase Inhibitor and With a Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Lower or Greater Than 3%

graphic file with name medi-95-e3780-g003.jpg